Dosiomics improves prediction of locoregional recurrence for intensity modulated radiotherapy treated head and neck cancer cases

被引:52
|
作者
Wu, Aiqian [1 ]
Li, Yongbao [2 ]
Qi, Mengke [1 ]
Lu, Xingyu [1 ]
Jia, Qiyuan [1 ]
Guo, Futong [1 ]
Dai, Zhenhui [3 ]
Liu, Yuliang [1 ]
Chen, Chaomin [1 ]
Zhou, Linghong [1 ]
Song, Ting [1 ]
机构
[1] Southern Med Univ, Dept Biomed Engn, Guangzhou 510515, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
[3] Guangzhou Univ Chinese Med, Dept Radiat Oncol, Affiliated Hosp 2, Guangzhou 510120, Guangdong, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
Dosiomics; Radiomics; Prognosis; Locoregional recurrences; Intensity-modulated radiotherapy; 3D dose distribution; Head and neck cancer; PROGRESSION-FREE SURVIVAL; LOCAL TUMOR-CONTROL; TEXTURAL FEATURES; RADIOMIC ANALYSIS; PROGNOSTIC VALUE; SALIVARY-GLANDS; FRACTIONATION; XEROSTOMIA; SIGNATURE; PATTERNS;
D O I
10.1016/j.oraloncology.2020.104625
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To investigate whether dosiomics can benefit to IMRT treated patient's locoregional recurrences (LR) prediction through a comparative study on prediction performance inspection between radiomics methods and that integrating dosiomics in head and neck cancer cases. Materials and Methods: A cohort of 237 patients with head and neck cancer from four different institutions was obtained from The Cancer Imaging Archive and utilized to train and validate the radiomics-only prognostic model and integrate the dosiomics prognostic model. For radiomics, the radiomics features were initially extracted from images, including CTs and PETs, and selected on the basis of their concordance index (CI) values, then condensed via principle component analysis. Lastly, multivariate Cox proportional hazards regression models were constructed with class-imbalance adjustment as the LR prediction models by inputting those condensed features. For dosiomics integration model establishment, the initial features were similar, but with additional 3-dimensional dose distribution from radiation treatment plans. The CI and the Kaplan-Meier curves with log-rank analysis were used to assess and compare these models. Results: Observed from the independent validation dataset, the CI of the model for dosiomics integration (0.66) was significantly different from that for radiomics (0.59) (Wilcoxon test, p = 5.9 x 10(-31)). The integrated model successfully classified the patients into high- and low-risk groups (log-rank test, = xp 2.5 10(-02)), whereas the radiomics model was not able to provide such classification (log-rank test, p = 0.37). Conclusion: Dosiomics can benefit in predicting the LR in IMRT-treated patients and should not be neglected for related investigations.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Evaluation of Arc-based Intensity Modulated Radiotherapy for Head and Neck Cancer
    Rao, M.
    Yang, W.
    Chen, F.
    Sheng, K.
    Ye, J.
    Vivek, M.
    Shepard, D.
    Cao, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S419 - S419
  • [42] Evaluation of dysphagia in head and neck cancer patients undergoing Intensity Modulated Radiotherapy
    Bashir, I.
    Bansal, K.
    Chufal, K.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S503 - S503
  • [43] Target volume delineation for head and neck cancer intensity-modulated radiotherapy
    Lapeyre, M.
    Toledano, I.
    Bourry, N.
    Bailly, C.
    Cachin, F.
    CANCER RADIOTHERAPIE, 2011, 15 (6-7): : 466 - 472
  • [44] Intensity-modulated Radiotherapy for Head and Neck Cancer: a Review of Toxicity and Outcome
    Maclean, J. D.
    Michaelidou, A.
    Sibtain, A.
    CLINICAL ONCOLOGY, 2009, 21 (03) : 273 - 273
  • [45] Dosimetric and Volumetric impact of Intensity Modulated Adaptive Radiotherapy in Head Neck Cancer
    Mitra, S.
    Dewan, A.
    Aggarwal, S.
    Wahi, I. Singh
    Barik, S.
    Dobriyal, K.
    Mukhee, J.
    Dewan, A. K.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S917 - S917
  • [46] DOSIMETRIC PREDICTORS FOR SWALLOWING DYSFUNCTION IN HEAD AND NECK CANCER TREATED WITH HYPERFRACTIONATED ACCELERATED INTENSITY MODULATED RADIOTHERAPY.
    Houghton, F.
    McNiven, A.
    O'Sullivan, B.
    Waldron, J.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S85 - S85
  • [47] OUTCOMES OF PATIENTS WITH HEAD-AND-NECK CANCER OF UNKNOWN PRIMARY ORIGIN TREATED WITH INTENSITY-MODULATED RADIOTHERAPY
    Shoushtari, Asal
    Saylor, Drew
    Kerr, Kara-Lynne
    Sheng, Ke
    Thomas, Christopher
    Jameson, Mark
    Reibel, James
    Shonka, David
    Levine, Paul
    Read, Paul
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (03): : E83 - E91
  • [48] Adenoid cystic carcinoma of the head and neck: Patterns of recurrence and implications for intensity-modulated radiotherapy
    Gao, Robert W.
    Routman, David M.
    Harmsen, William S.
    Ebrahimi, Sasha
    Foote, Robert L.
    Ma, Daniel J.
    Neben-Wittich, Michelle
    McGee, Lisa A.
    Patel, Samir H.
    Moore, Eric J.
    Choby, Garret W.
    Tasche, Kendall K.
    Price, Katharine A.
    Gamez, Mauricio E.
    Lester, Scott C.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2023, 45 (01): : 187 - 196
  • [49] Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy
    Huguenin, P
    Beer, KT
    Allal, A
    Rufibach, K
    Friedli, C
    Davis, JB
    Pestalozzi, B
    Schmid, S
    Thöni, A
    Ozsahin, M
    Bernier, J
    Töpfer, M
    Kann, R
    Meier, UR
    Thum, P
    Bieri, S
    Notter, M
    Lombriser, N
    Glanzmann, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) : 4665 - 4673
  • [50] MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy
    Ahmad, Parwez
    Sana, Jiri
    Slavik, Marek
    Gurin, Dominik
    Radova, Lenka
    Gablo, Natalia Anna
    Kazda, Tomas
    Smilek, Pavel
    Horakova, Zuzana
    Gal, Bretislav
    Hermanova, Marketa
    Slampa, Pavel
    Slaby, Ondrej
    CANCER GENOMICS & PROTEOMICS, 2019, 16 (02) : 139 - 146